Neogenomics Inc Stock Price, News & Analysis

NeoGenomics, Inc. (NASDAQ:NEO) announced the release date for its third quarter 2022 financial results, set for November 8, 2022. The company will conduct a webcast and conference call at 8:30 AM EDT on the same day to discuss the results. Interested parties can participate by calling specific access numbers. A replay will be available until November 22, 2022. NeoGenomics specializes in cancer-focused genetic testing and operates several accredited labs across the U.S. and internationally.

NeoGenomics (NASDAQ: NEO) announces presentations of new research at the ESMO Congress from September 9-13, 2022. The studies showcase the RaDaR™ assay, which proved effective in detecting minimal residual disease in head and neck squamous cell carcinoma patients. Additionally, early findings suggest PAK4 as a potential biomarker for poor immunotherapy response in melanoma patients. These developments highlight the assay's applicability across tumor types, aiming to enhance cancer treatment decisions and outcomes.

NeoGenomics, Inc. (Nasdaq:NEO) announced equity inducement awards for new CEO Chris Smith, as mandated by Nasdaq Listing Rules. The awards include 336,767 restricted stock shares, a sign-on award of 265,452 restricted shares, and a stock option for 694,444 shares, all effective from August 15, 2022. The restricted stock will vest over time, contingent on continued service, while the stock option has a seven-year term with an exercise price of $12.62. These grants aim to incentivize and retain the new CEO as the company excels in oncology testing and research services.

NeoGenomics, Inc. (NASDAQ: NEO) has appointed Chris Smith as CEO, effective August 15, 2022. Smith, previously CEO of Ortho Clinical Diagnostics, brings extensive experience in the diagnostic industry. He is expected to lead NeoGenomics in navigating the growing oncology market. Alongside him, Lynn Tetrault will transition to the role of independent Chair of the Board. The company operates globally with a focus on cancer genetics testing, aiming to enhance patient care and treatment innovation.

NeoGenomics, Inc. (NASDAQ: NEO) announced it will release its second quarter 2022 financial results on August 9, 2022. A conference call will be held at 8:30 AM EDT that day to discuss the results. Interested parties can join by calling (877) 545-0523 for domestic or (973) 528-0016 for international access. The call will also be available for replay until August 23, 2022. NeoGenomics specializes in cancer genetics testing and services, and operates certified laboratories across the U.S. and internationally.

NeoGenomics, Inc. (NASDAQ: NEO) announces new data from its subsidiary Inivata, supporting the RaDaR^TM assay for detecting minimal residual disease (MRD) in high-risk HR+ HER2- breast cancer patients. The CHiRP study revealed that 10% of patients had positive MRD results, with ctDNA identified a median of one year before distant metastasis. The study emphasizes RaDaR's potential for early tumor recurrence detection, potentially leading to timely intervention. The findings were published in the Journal of Clinical Oncology and were presented at the ASCO Annual Meeting.

NeoGenomics, Inc. (NASDAQ: NEO) announced its participation in several institutional investor conferences. Management will present at the William Blair 42nd Annual Growth Stock Conference on June 8, 2022, at 12:20 pm ET, with a live webcast available on the company's website. Additionally, they will conduct investor meetings at the Goldman Sachs 43rd Annual Global Healthcare Conference on June 13, 2022. NeoGenomics specializes in cancer genetics testing and services, emphasizing patient support and compliance with data protection laws.

NeoGenomics, Inc. has achieved CAP certification for its Suzhou laboratories with zero deficiencies, enhancing its capabilities in oncology drug development for clients in China. This certification will benefit global pharmaceutical partners by facilitating clinical trials from early discovery research to drug development. The company has established partnerships with local CROs and offers a variety of testing services including next-generation sequencing. The strategic move aims to strengthen NeoGenomics' position in the growing biopharma sector.

NeoGenomics, Inc. (NASDAQ:NEO) announced the appointment of Lynn Tetrault as Chair of the Board and Interim CEO effective May 12, 2022, following the previous CEO's resignation. Tetrault, who has been with the company since 2015, will ensure operational continuity during the search for a permanent CEO. The company also disclosed the departure of Douglas Brown, Chief Strategy and Corporate Development Officer, on May 27. The firm remains focused on enhancing operational efficiency and providing extensive cancer genetic testing services.